## Nevirapine

**Section:** 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.2. Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

### Essential medicine status

- **INN:** Nevirapine
- **Medicine type:** Chemical agent
- **List type:** Core (EML) (EMLc)
- **ATC codes:** J05AG01

### Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

**ICD11 code:** 1C62.Z

### Formulations

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg (EML)

### EML status history

- First added in 1999 (TRS 895)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2015 (TRS 994)
- Changed in 2023 (TRS 1049)

### Sex

- All

### Age

- Also recommended for children

### Age restriction

- > 6 weeks

### Therapeutic alternatives

The recommendation is for this specific medicine

### Patent information

- Patents have expired in most jurisdictions
  - Read more about patents.

### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an "optimal" paediatric formulation.